Full Breakdown
Engineered “Cyto-Gel” Accelerates Blood Clotting and Enhances Tissue Regeneration
4/30/2026, 11:09:17 AM
Engineered Cyto-Gel Enables Rapid Hemostasis
Researchers at McGill University and collaborators have engineered a red-blood-cell–based biomaterial, Cyto-Gel, that forms a clot in seconds and markedly reduces blood loss from severe wounds.
Background: Prior Hemostatic Biomaterials
Previous hemostatic approaches include chitosan gels, liquid-infused adhesives, and barnacle-inspired pastes, which often rely on fibrin or synthetic polymers and can be brittle or provoke immune reactions.
Key Researchers and Funding
The work was led by Jianyu Li (McGill, Canada Research Chair) and PhD student Shuaibing Jiang (now at Harvard). Co-authors include Hyunwoo Yuk (SanaHeal), Jayachandran Kizhakkedathu (U-BC), and teams at Colorado Boulder, Toronto, Versiti, and the Medical College of Wisconsin. Funding came from the Canadian Institutes of Health Research and the New Frontiers in Research Fund – Exploration.
Rodent Liver Model Demonstrates Rapid Clotting
In rats with severe liver lacerations, Cyto-Gel–treated plasma produced visible clots within five seconds versus 265 seconds in controls. Treated animals lost ~24 mg of blood compared with ~2000 mg in untreated rats, and clots remained intact for 1–2 months without organ toxicity.
Performance Metrics
Cyto-Gel shows 13-fold higher fracture resistance and four-fold greater adhesive strength than natural clots. Autologous preparation takes ~20 minutes; allogeneic preparation <10 minutes. Shelf-life is currently about one month when refrigerated.
Clinical Relevance
The ability to stop bleeding within seconds could improve outcomes in planned surgery, trauma, and coagulation disorders such as hemophilia, while also supporting tissue regeneration, as shown by enhanced liver healing in rodents.
Official Statements & Responses
Li highlighted that engineered red blood cells provide a structural backbone that overcomes the fragility of natural clots. Yuk called the work a new design method for cell-based biomaterials. The team noted suitability for both autologous and allogeneic use and a pending patent.
Criticism & Concerns
Kizhakkedathu warned that synthetic hemostats have longer shelf lives, posing logistical challenges for the cell-based product.
Conflicting Reports & Gaps
All data are from in-vitro tests and rodent studies; no human trials have been reported, and independent verification of mechanical claims is pending.
Verbatim Quotes
- “It is exciting work that shows a new design method for cell-based biomaterials for surgical and regenerative applications,” — Hyunwoo Yuk, founder of SanaHeal
- “One challenge could be the shorter shelf life of such cellular materials, unlike synthetic materials,” — Jayachandran Kizhakkedathu, University of British Columbia
- “Natural blood clots can be slow to form and mechanically fragile, which limits their ability to stop severe bleeding and can compromise healing,” — Jianyu Li, senior author
- “This study can be utilized in the development of biomaterials to control severe hemorrhage,” — Research team (Dongascience)
What’s Next
The team has filed a patent and will conduct pre-clinical safety studies before initiating human trials to evaluate efficacy, storage stability, and regulatory pathways. Scaling production for emergency blood-bank use and testing in patients with clotting disorders are planned milestones.
